Matthew Perry - Mar 9, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
Director
Signature
/s/ Matthew D. Perry
Stock symbol
CTIC
Transactions as of
Mar 9, 2022
Transactions value $
$0
Form type
4
Date filed
3/11/2022, 06:46 PM
Previous filing
May 21, 2021
Next filing
May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Stock Option (right to buy) Award $0 +80K $0.00 80K Mar 9, 2022 Common Stock 80K $4.49 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2023 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event.
F2 The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.